key: cord-0921791-tu15f2do
authors: Freire-Paspuel, Byron; Garcia-Bereguiain, Miguel Angel
title: Low Clinical Performance of "Isopollo COVID19 detection kit" (Monitor, South Korea) for RT-LAMP SARS-CoV-2 diagnosis: a call for action against low quality products for developing countries
date: 2021-01-09
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.12.088
sha: 74c4eb5349d66246ee62031dbee00398b460ea24
doc_id: 921791
cord_uid: tu15f2do

Background Multiple molecular kits are available for SARS-CoV-2 diagnosis worldwide, lot of them lacking of proper clinical evaluation due to the emergency caused by COVID-19 pandemic, particularly at developing countries. Objective We evaluated the clinical performance of "Isopollo COVID19 detection kit" (Monitor, South Korea) for RT-LAMP SARS-CoV-2 diagnosis using SARS-CoV-2 RT-PCR protocol as a gold standard. Results 220 clinical samples were included on the study; 168 samples were SARS-CoV-2 positive and 52 samples were SARS-CoV-2 negative according to SARS-CoV-2 RT-PCR protocol. For "Isopollo COVID19 detection kit', only 104 out of 168 samples were SARS-CoV-2 positive. This result shows a low clinical performance with sensitivity of 61.9% for the evaluated RT-LAMP assay. Conclusions Proper clinical performance evaluation studies from regulatory agencies at developing countries like Ecuador should be mandatory prior to clinical use authorization of SARS-CoV-2 diagnosis kits, particularly when those kits lack of either FDA or country of origin clinical use authorization

The COVID-19 pandemic has challenged public health systems worldwide, not only for patient care or pandemic surveillance and control, but also to guarantee the quality of SARS-CoV-2 diagnosis tools. For instance, multiple SARS-CoV-2 molecular diagnosis kits are available on the market, most of them based on RT-qPCR but also someones based on RT-LAMP. Some of them have received emergency use authorization (EUA) from the U.S. Food & Drug Administration (FDA) (1), or at least by regulatory agencies at their country of production, while others only report clinical evaluation studies made by the manufacturers Among the kits available in the market, the CDC designed 2019-nCoV CDC EUA kit (IDT, USA) is based on N1 and N2 gene targets to detect SARS-CoV-2 that have received positive evaluation on recent reports, and RNaseP gene target as an RNA extraction quality control, and it is considered a gold standard for clinical evaluation (2) (3) (4) (5) (6) . "Isopollo COVID19 detection kit" (Monitor, South Korea) is a fluorescence based RT-LAMP kit that include two gene targets "RdRp" and "N" for SARS-CoV-2 detection, but no target for RNA extraction quality control; moreover, this RT-LAMP kit does not have EUA approval J o u r n a l P r e -p r o o f neither from FDA (USA) nor from Korean CDC (1,7), but it is currently available in Ecuador for SARS-CoV-2 clinical diagnosis.

The aim of this study was to evaluate the clinical performance and analytical sensitivity for "Isopollo COVID19 detection kit" using the SARS-CoV-2 RT-PCR CDC protocol as a gold standard.

Study design. 220 clinical specimens (nasopharyngeal swabs collected on 0.5mL TE pH 8 buffer)

were included in this study. Also, 10 negative controls (TE pH 8 buffer) were included as control for carryover contamination, one for each set of RNA extractions.

included on the study were tested following an adapted version of the CDC protocol previously reported by our lab (8) (9) (10) (11) (12) (13) .

RT-LAMP for SARS-CoV-2 diagnosis using "Isopollo COVID19 detection kit". Same RNA extractions from all the samples included on the study were tested using "Isopollo COVID19 detection kit'.

Quality of RNA was tested by running RT-qPCR for RNaseP probe. Initially, 128 samples were processed using a final volume of reaction of 15uL (7.5uL of "reaction buffer 2x"; 0.6uL of "enzyme mix"; 1.2 uL of "primers mix"; 0.6 uL of "RNase free water"; 5uL of RNA extraction).

Secondly, 92 samples were processed using a final volume of reaction of 25uL, following manufacturer's manual. to copies/mL of nasopharyngeal sample. For "Isopollo COVID19 detection kit", a positive control is included on the kit but the concentration is not detailed, so it was not possible to calculate the LoD.

Ethics statement. All samples have been submitted for routine patient care and diagnostics.

Ethics approval was not sought because the study involves laboratory validation of test methods and the secondary use of anonymous pathological specimens that falls under the category 'exempted' by Comité de Etica para Investigación en Seres Humanos" from "Universidad de Las Américas".

Clinical performance of "Isopollo COVID19 detection kit" compared to the SARS-CoV-2 RT-PCR CDC gold standard protocol. 220 samples were tested for SARS-CoV-2 following both protocols described on the methods.

The first set of 128 samples was processed with the CDC protocol and "Isopollo COVID19 In summary, while the overall specificity for "Isopollo COVID19 detection kit" was 100%, the overall sensitivity compared to the CDC protocol was 61.9%, as 104 out of 168 SARS-CoV-2 positives samples were detected (Table 1) .

The viral loads detailed on Supplementary Table 1 and 2 were calculated running a calibration curve with 2019-nCoV N positive control (IDT, USA). The LoD for the CDC protocol was set at 1000 viral RNA copy per mL of sample (or 5 RNA copies/uL of RNA extraction solution) on previous studies (2, 6, (8) (9) (10) (11) (12) . Although LoD could not be calculated for "Isopollo COVID19 detection kit" as we described on the methods, even for samples with viral loads above 100.000 RNA copies/mL (500 RNA copies/uL of RNA extraction solution) , only 81 out of 88 (92.04%) samples were also positive for "Isopollo COVID19 detection kit". As the LoD is defined as the lowest viral load in which all replicates are detected (100% sensitivity), our data indicates that the LoD for "Isopollo COVID19 detection kit" would be higher than 100.000 RNA copies/mL of sample.

The results presented on this study support that "Isopollo COVID19 diagnosis kit" has a poor clinical performance with a reduction of sensitivity up to 38.1% compared to the CDC protocol.

Moreover, these findings are particularly worrying considering that the amplification of a single viral target is enough to consider a sample as SARS-CoV-2 positive with the "Isopollo COVID19 detection kit", while two viral targets amplification is required by the CDC protocol (2, 3, 6) . Also, the lack of any gene target for RNA extraction quality control like RNaseP, and the unreported J o u r n a l P r e -p r o o f concentration of positive controls provided for "Isopollo COVID19 kit" that does not allow viral load calculations, are also limitations to be considered when using this kit.

As we have detailed on the text, the LoD for "Isopollo COVID19 detection kit" is estimated to be higher that 100.000 viral copies/mL of sample, as only 81 of of 88 samples included on the study with viral loads above that LoD were actually detected as positive. Considering the viral loads frequency distribution for SARS-CoV-2, this high LoD would potentially affect to more than 30% of true positive cases if "Isopollo COVID19 detection kit" is used for surveillance programs (14, 15) . "Isopollo COVID19 detection kit" neither has EUA FDA nor Korean CDC EUA (1,7), so it is not actually used for clinical diagnosis on its country of production. However, it is available in Ecuador, where no evaluation studies are carried out by the governmental regulatory agency responsible for clinical use authorization for SARS-CoV-2 diagnosis. Under this scenario, the municipal government of Quito (capital city of Ecuador with a population over 2 million people) purchased "Isopollo COVID19 kits" for around 100.000 RT-LAMP tests (16). Although we reported the results presented on this study to Quito authorities, they decided to ask for an extra evaluation study by a private diagnosis laboratory. In this study, where neither viral loads nor Ct values of the SARS-CoV-2 samples are detailed, there is also a reduction of sensitivity up to 14%; moreover, this study included a bigger number of negative samples that ours, and a reduction specificity up to 5% was reported (17). Unfortunately, "Isopollo COVID19 diagnosis kit" is been used by the government of city of Quito, despite our warnings of the risk of the high rate of false positive and false negative diagnosis on a massive surveillance program.

Considering the worldwide high demand of reagents for SARS-CoV RT-qPCR diagnosis, supplies shortage is a fact and multiple companies market recently developed diagnosis kits. Under this J o u r n a l P r e -p r o o f

US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. Emerging Infectious Diseases

Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)

Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. Accepted Manuscript Posted Online 17

Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit. JCM Accepted Manuscript Posted Online 8

Evaluation of nCoV-QS (MiCo BioMed) for RT-qPCR Detection of SARS-CoV-2 From Nasopharyngeal Samples Using CDC FDA EUA qPCR Kit as a Gold Standard: An Example of the Need of Validation Studies

COVID-19 Task Force and the Center for Laboratory Control of Infectious Diseases, the Korea Centers for Disease Control and Prevention. Guidelines for Laboratory Diagnosis of Coronavirus Disease

Cotton-Tipped Plastic Swabs for SARS-CoV-2 RT-qPCR Diagnosis to Prevent Supply Shortages. Front Cell Infect Microbiol

Miguel Angel Garcia-Bereguiain. Sample pooling of RNA extracts to speed up SARS-CoV-2 diagnosis using CDC FDA EUA RT-qPCR kit

Analytical sensitivity and clinical performance of a triplex RT-qPCR assay using CDC N1, N2 and RP targets for SARS-CoV-2 diagnosis

Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis

Poor sensitivity of "AccuPower SARS-CoV-2 real time RT-PCR kit

One Health" inspired SARS-CoV-2 surveillance: The Galapagos Islands experience. One Health

Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo

Accelerated Article Preview Published online 30

SARS-CoV-2 Viral load Assessment in Respiratory Samples

Table 1. Clinical performance of "Isopollo COVID19 detection kit" compared to CDC protocol (Value of 100% and 61.9% corresponds to specificity and sensitivity, respectively)